<DOC>
	<DOCNO>NCT01852058</DOCNO>
	<brief_summary>This study evaluate long-term safety efficacy onabotulinumtoxinA treatment urinary incontinence due neurogenic detrusor overactivity patient successfully complete Study 191622-120 .</brief_summary>
	<brief_title>A Long-Term Extension Study OnabotulinumtoxinA Urinary Incontinence Due Neurogenic Detrusor Overactivity</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Successfully complete participation Study 191622120 Aged ≥ 5 year ≤ 17 year time entry Study 191622120 Regularly use clean intermittent catheterization empty bladder Myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis Current plan use baclofen pump Current plan use electrostimulation/neuromodulation device urinary incontinence Use indwelling catheter urinary incontinence instead use clean intermittent catheterization empty bladder Previous current use botulinum toxin therapy serotype urological condition , treatment botulinum toxin serotype condition since enter study 191622120</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>